Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00813189
Other study ID # 2004/64
Secondary ID
Status Completed
Phase Phase 3
First received December 19, 2008
Last updated May 4, 2015
Start date April 2005
Est. completion date May 2012

Study information

Verified date May 2015
Source Association REMEDE
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

Children suffering from chronic disease and receiving long-term glucocorticoid therapy suffer over years from severe growth retardation and profoundly altered body composition. They consist in a marked increase in fat mass and a decrease in lean body mass. Published studies have shown that Growth Hormone (GH) treatment in children with Juvenile Idiopathic Arthritis can improve body composition by increasing lean mass and by preventing increase in fat mass. The aim of the present protocol is to evaluate whether the increase in lean body mass observed during GH treatment is associated with changes in muscle strength and mass.

In order to be able to evaluate the effect of GH on the muscle a comparative group is needed. Therefore it will be proposed to delay in a group of patients the start of Growth Hormone(GH) treatment by 6 months. As most publications have shown a maximum effect of GH within the first year of treatment, six months should be enough to evaluate short-term effect of GH on the muscle. Therefore, this study will be a randomized trial: immediate start of Growth Hormone (GH) treatment versus start of Growth Hormone treatment 6 months later. After 6 months all children will be treated with GH. Therefore, the follow-up will be one year after baseline.


Description:

The aim of the present protocol is to evaluate the effects of GH treatment in long-term steroid treated children, on muscle mass, and muscle strength. It will be an open, randomized, controlled, 2-parallel group study. The follow-up in this study will be one year. The objective of this study will be to evaluate short-term effects of GH treatment on muscle mass, muscle strength and body composition in children suffering from various diseases requiring steroid therapy. Expected pathologies are juvenile idiopathic arthritis, nephrotic syndrome, uveitis, systemic diseases and organ transplantation. Changes in muscle mass will be assessed by measuring the muscle and sub-cutaneous fat on the cross sectional area of the thigh by MRI. MRI offer the advantage of non-invasive technique, allowing serial and accurate measurements.Muscle strength will be performed by serial muscular testing of different muscular groups. Body composition will be assessed by DEXA. DEXA allows rapid, accurate and highly reproductible determination not only of bone mass but also of lean and fat mass of the whole body, with very low radiation exposure.It appears to be the most sensitive method for assessment of muscle wasting as well as of fat repartition that contribute to Cushing's appearance in steroid treated patients.

The present study will be performed in children with growth retardation related to long-term glucocorticoid treatment These patients had never been treated with GH. In order to be able to evaluate the effect of GH on the muscle a comparative group is needed. Therefore it will be proposed in the study to delay in a group of patient the start of GH treatment by 6 months. Six months should be enough to evaluate short-term effect of GH on the muscle and most publication have shown a maximum effect of GH within the first year of treatment. Therefore, this study will be a randomized trial: immediate start of GH treatment versus start of GH treatment 6 months later. After 6 months all children will be treated with GH. The dose administered in the present trial will be a GH dose already tested in glucocorticoid treated children (0.46 mg/kg/week)


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 2012
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender Both
Age group 6 Years and older
Eligibility Inclusion Criteria:

- Measured Height below -2 SD

- Bone age below 13 years for a boy and below 11 years for a girl

- Glucocorticosteroid treatment for 12 months at least

- Glucocorticosteroid dose above or equal to 0.2 mg/kg/day of prednisone or equivalent dose over the last 12 months

- Glucocorticosteroid treatment is anticipated to be sustained for 1 more year at least

- The child benefits of the French social security cover

- Child who has never been treated by GH.

- Evidence of a personally signed and dated informed consent document indicating that the patient's parents/guardians and from the patient himself/herself if he/she is able to receive and understand the information have been informed of all pertinent aspects of the study.

- No glucose intolerance or diabetes mellitus on an Oral Glucose Tolerance Test dated less than 3 months

Exclusion Criteria:

- Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
GH treatment
GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.

Locations

Country Name City State
France Hôpital Robert Debré Paris

Sponsors (2)

Lead Sponsor Collaborator
Association REMEDE Pfizer

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The main criteria of efficacy will be - the mean strength changes assessed as a composite score (mean of the relative changes of the ten muscle functions tested): ? strength as % of baseline values :6 months-baseline. 6 months No
Secondary Strength changes assessed as a composite score (mean of the relative changes of the ten muscle functions tested) as % of baseline values : 12 months-baseline and 12 months- 6 months, 18 months- 6 months for group B patients 18 months No
See also
  Status Clinical Trial Phase
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Recruiting NCT06058754 - Group-based [ADAPT] Versus One-to-one [Usual] Occupational Therapy (Go:OT Trial) N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05558085 - Biomarker Cost-Benefit Analysis of EFNEP N/A
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Not yet recruiting NCT05622422 - A Chronic Disease Self Care Management Pilot Study N/A
Not yet recruiting NCT06016101 - Usefulness of the Medissimo Nurse Application for Supporting Medication Compliance in Elderly People With Chronic Polypathologies
Not yet recruiting NCT04954209 - Comparative Study in Long-term Commitment to Physical Activity After Two Different Resumption Programs
Not yet recruiting NCT04090593 - Chronic Disease Mobile Educational Experience N/A
Not yet recruiting NCT03628963 - Optimizing Patient Usability Experience for Chronic Care N/A
Completed NCT02390570 - Incorporating Patient Capacity Into the Clinical Landscape N/A
Completed NCT02072941 - Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making (PREPARE) N/A
Completed NCT02292940 - Consumer Health IT Tools: Impact on Experience, Access, and Outcomes for Patients With Complex Chronic Conditions
Completed NCT02017262 - Group Self-Management of Depression and Medical Illness N/A
Terminated NCT02115971 - Jumping Exercises Approach in Individuals With Chronic Ankle Instability N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Completed NCT02307929 - Evaluation of Quality of Care - Nurse Allied Health Clinic Programme, HA N/A
Completed NCT01458184 - Study of PhoneCare System to Treat Patients With Chronic Diseases N/A
Completed NCT00380536 - Medical Self-Management for Improving Health Behavior Among Individuals in Community Mental Health Settings N/A
Completed NCT00333710 - Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD N/A